Figure 7. Twist1 in podocytes suppresses macrophage accumulation in glomeruli and renal interstitium after NTS injury.

(A) Representative flow plots of CD11b⁺CCR2⁺ macrophages from kidneys of NTS-treated WT and Twist1-PKO animals. (B) Absolute numbers of CD11b⁺CCR2⁺ macrophages per gram of WT or Twist1-PKO kidney (n = 7, t test). (C) Representative flow plots of CD11b⁺Ly6C^hi-infiltrating monocytes from kidneys of NTS-treated WT and Twist1-PKO animals. (D) Absolute numbers of CD11b⁺Ly6C^hi-infiltrating monocytes per gram of WT and Twist1-PKO kidney (n = 7, t test). (E) Representative sections of CD64-stained glomeruli from NTS-treated WT and Twist1-PKO animals. Scale bar: 40 μm. (F) Quantitative determination of glomerular CD64-positive cells in NTS-treated WT and Twist1-PKO cohorts (n = 7, t test). (G) Representative CD64-stained kidney sections from NTS-treated WT and Twist1-PKO mice. Scale bar: 100 μm. (H) Quantitative determination of kidney interstitial CD64-positive cells in NTS-treated WT and Twist1-PKO cohorts (n = 7, t test). All t tests were 2 tailed. *P < 0.05. NTS, nephrotoxic serum; Twist1-PKO, Pod-Cre Twist1^fl/fl.